Pomalidomide Patent Expiration
Pomalidomide is used for treating multiple myeloma in patients who have already received other prior therapies. It was first introduced by Bristol Myers Squibb Co
Pomalidomide Patents
Given below is the list of patents protecting Pomalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pomalyst |
US8828427 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Dec 21, 2031 | Bristol |
| Pomalyst | US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Jun 21, 2031 | Bristol |
| Pomalyst |
US10555939 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
| Pomalyst |
US9993467 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
| Pomalyst | US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst | US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst |
US8198262 (Pediatric) | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec 17, 2025
(Expired) | Bristol |
| Pomalyst | US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun 17, 2025
(Expired) | Bristol |
| Pomalyst |
US8673939 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst |
US8735428 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst | US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst | US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6316471 | Isoindolines, method of use, and pharmaceutical compositions |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US8158653 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US5653517 | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US6476052 | Isoindolines, method of use, and pharmaceutical compositions |
Jul 24, 2016
(Expired) | Bristol |
Pomalidomide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pomalidomide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
